Global Blood Therapeutics, Inc.
GBTDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001629137
Global Blood Therapeutics, Inc. was delisted in 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.75B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 247
- Q3 2022, +53 vs. previous quarter
- 13F value
- $4.67B
- Reported value at the end of Q3 2022
- Superinvestors holding
- 1
- At the end of Q3 2022
Superinvestors holding GBT, Q3 2022
1 superinvestor reports holding Global Blood Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.0%
Global Blood Therapeutics, Inc.'s share of the portfolio
- Shares
- 1
- Value
- $0
Latest insider trades
Open-market purchases and sales by Global Blood Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Farrow Jeffrey SChief Financial Officer | SSale | −31.4K | $68.00 | −$2.14M | −91.1%3.09K after | |
| Aug 19, 2022 (view filing) | Aug 18 | 1 day | Habibizad NazilaSee Remarks | SSale | −4.68K | $67.19 | −$314.3K | −34.4%8.92K after | |
| Jun 22, 2022 (view filing) | Jun 21 | 1 day | Pizzo Philip A.Director | SSale | −1.26K | $27.25 | −$34.3K | −12.1%9.11K after | |
| Jun 22, 2022 (view filing) | Jun 21 | 1 day | Svoronos DawnDirector | SSale | −1.91K | $27.24 | −$52.0K | −26.2%5.38K after | |
| Sep 10, 2021 (view filing) | Sep 9 | 1 day | Morrison Scott WDirector | SSale | −4.80K | $30.21 | −$145.0K | −61.2%3.04K after |
Top 10 13F holders, Q3 2022
The largest institutional positions in Global Blood Therapeutics, Inc. at the end of Q3 2022; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 6,282,173 | $427.8M | 0.01% | +262,742+4.4% | Added |
| BlackRock Inc. | 4,749,863 | $323.5M | 0.01% | −22,528−0.5% | Reduced |
| Baker Bros. Advisors LP | 3,732,502 | $254.2M | 1.66% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 3,200,000 | $217.9M | 3.30% | +3,200,000 | New |
| State Street Corp | 2,384,677 | $162.4M | 0.01% | −2,038,867−46.1% | Reduced |
| Perceptive Advisors LLC | 2,322,247 | $158.1M | 4.60% | −692,807−23.0% | Reduced |
| JPMorgan Chase & Co | 2,304,636 | $156.9M | 0.02% | +1,898,523+467.5% | Added |
| FIL Ltd | 2,263,000 | $154.1M | 0.20% | +2,263,000 | New |
| UBS Oconnor LLC | 2,238,787 | $152.5M | 1.75% | +2,238,787 | New |
| Goldman Sachs Group Inc | 1,706,600 | $116.2M | 0.03% | +1,033,433+153.5% | Added |